Affordable Care Act: Exit, Stage Right

WIll the Affordable Care Act be lost in transition, and how will these changes affect hematologists and their patients?

Learn more

Editor's Corner

Mikkael Sekeres recounts the anxiety-inducing experience of watching a junior colleague present at the Annual Meeting

Learn more

Highlights from the ASH Annual Meeting

Double Hematopoietic Cell Transplantation Extends Progression-Free Survival Over Single Transplant in Myeloma Patients

Learn more

Written in Blood

Long-Term Analysis Identifies Encouraging Trends in Hemophilia A Care

Learn more

You Make the Call

Should I give CHOP-based therapy to a patient with peripheral T-cell lymphoma NOS?

Learn more

New Exclusive Videos

View all Exclusive Videos

  • Learning to Love Your Genome

    The daily circus of recent world events has left me wondering whether it is truly plausible that I share a genome with the other half of the population, or whether my alienation could be explained by a heavy burden of Neanderthal DNA or excessive cilantro hypersensitivity (it’s a thing – look it up). To explore […]

  • Microphone Moment

    Entering Monday’s oral abstract session at the 2016 ASH Annual Meeting, my goals were twofold: to see some great science that may influence how I care for my patients and to support my colleague – a faculty member a couple of years out of fellowship. It wasn’t that long ago (or so I keep telling […]

  • Making a Hematology Wishlist, and Checking it Twice

    Happy New Year! Can you believe it’s 2017 already? Another holiday season passed, another calendar page flipped, another year gone by. I thought that I was pretty good this year, earning a spot on the “nice” list, but Santa still didn’t leave all the presents I wanted under the tree. Here’s a sampling of gifts […]

  • So You Say You Want To Be A Clinical Researcher?

    Perhaps you’ve just finished your hematology/oncology fellowship a year or two ago. Or you’re still a fellow and, having completed that intensive first year of inpatient consults and the speed dating outpatient rotations in different specialty clinics, you’ve just woken up to the realization that you have to apply for jobs in a year. Or […]

View all Editor`s Corner
  • To Test or Not to Test: Is Pharmacogenomic Testing for Warfarin Valuable?

    Warfarin has been standard anticoagulation for more than 60 years, but the significant variability in both warfarin pharmacokinetics and pharmacodynamics makes achieving therapeutic drug levels a challenge. Researchers are now investigating whether adding genomic information to dosing algorithms could better identify the optimal starting dose for patients new to warfarin, minimize variability in drug response, […]

  • Choosing Between Treatment Strategies for Patients With Acquired Hemophilia A

    Acquired hemophilia A (AHA) is a rare bleeding disorder in which patients develop inhibitors against clotting factors – most often factor VIII (FVIII). For nearly 10 years, the standard of care for the treatment of AHA was either recombinant factor VIIa (rFVIIa) or FVIII inhibitor bypass activity (FEIBA), known as a “bypassing agent” because it […]

  • FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?

    Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this population represents a therapeutic challenge – given their comorbidities and susceptibility to treatment-related toxicities. Patients who also harbor the FLT3 mutation face a particularly poor prognosis, with a high chance of […]

  • Optimal Timing of Transplant in Myeloma

    New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront stem cell transplantation. ASH Clinical News has invited Shaji Kumar, MD, and Ola Landgren, MD, to debate the question: “What is the optimal timing for hematopoietic cell transplantation in patients with […]

View all Drawing First Blood
  • CMS Tests New Medicare Part B Reimbursement Model: How Will It Affect Hematologists?

    In March, the Centers for Medicare & Medicaid Services (CMS) announced a proposed rule to test new models to improve Medicare Part B physician reimbursements for prescription drugs.1 According to CMS, the rule will test different physician incentives that would, in theory, encourage the prescription of the most effective drugs and reward positive patient outcomes. […]

  • Choosing Wisely Across the Internal Medicine Spectrum: Which Recommendations Should Hematologists Pay Attention To?

    In collaboration with the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign, ASH released a list of hematology-related tests and procedures to question based on recommendations from other medical societies at the 2015 annual meeting. Choosing Wisely encourages clinicians and patients to engage in conversations to reduce waste and overuse in health care. […]

  • New Medicare Care Choices Model Seeks to Expand Access to Palliative Care

    On July 20, 2015, the Centers for Medicare& Medicaid Services (CMS) announced the 141 hospices that have been selected to participate in the new Medicare Care Choices Model (MCCM), a pilot program designed to expand patients’ access to palliative and hospice care.1 The new model provides clinicians, beneficiaries, and their families with greater flexibility in deciding between hospice care and active […]

  • ICD-10: Ready or Not!

    After two one-year reprieves, it’s finally here: The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). Nationwide, on October 1, 2015, all health-care business transactions in the United States converted to ICD-10 from the previous version of the ICD (ICD-9). If they did not convert, claims and electronic transactions will be rejected. The ICD-9 […]

View all Practice Update